Centanafadine FDA Priority Review — Women's ADHD New Dimension. Perimenopausal Worsening·8.6-Year Life Expectancy Blind Spot

ADHD was perceived as childhood condition. But adult women ADHD shortens life expectancy by 8.6 years and perimenopausal worsening is common. Otsuka centanafadine 2026.4 FDA Priority Review accepted·PDUFA 2026.7.24 = women’s ADHD blind spot first clinical unit recognition.

Key Announcement

Centanafadine:

Triple Reuptake Inhibitor (NDS)
Norepinephrine·dopamine·serotonin simultaneous blockade
Non-stimulant (different from Adderall·Concerta)
Otsuka·Neurovance
FDA Priority Review accepted 2026.4
PDUFA 2026.7.24

Indications: Adult ADHD, adolescent ADHD, pediatric ADHD (simultaneous filing)

Clinical: Phase 3 adult·adolescent·pediatric complete, excellent efficacy + safety data

British Journal of Psychiatry 30,000 cohort:

Women ADHD life expectancy: 75.15 years
Non-ADHD women: 83.79 years
Gap: 8.64 years
Larger than men gap (men 4~5 years)

Causes:

Suicide risk ↑ (3~5x)
Accidents·trauma ↑
Drug·alcohol abuse
Comorbid depression·anxiety
Chronic disease (diabetes·cardiovascular) management ↓
Diagnosis·treatment delay (women 70% undiagnosed)

Diagnosis delay causes:

Childhood “inattention = boy” bias
Women ADHD = inattentive type predominant (hyperactivity ↓)
“Good girl” masking
Adolescent diagnosis rate 1/4 of boys

Mean diagnosis age:

Men: 7
Women: 36
Women 70% lifetime undiagnosed·misdiagnosed (as depression·anxiety)

Perimenopausal Worsening - Hormone-Dopamine Axis

Estrogen and dopamine:

Estrogen = dopamine signaling enhancement (natural ADHD med-like)
Estrogen ↓ → dopamine ↓ → ADHD symptoms ↑

Women ADHD hormonal pattern:

Puberty: symptom visualization
Pregnancy: some improvement·some worsening (individual)
Postpartum: postpartum ADHD worsening·overlap with PPD
Menstrual luteal phase: symptoms ↑
Perimenopause (40~50s): worst worsening
Post-menopause: some stabilization

Clinical meaning:

40~50s women ADHD diagnosis surge
“Early menopause·depression” misdiagnosis common
Hormone + ADHD integrated treatment needed

Centanafadine - New Dimension

Existing ADHD drugs:

Stimulants: Methylphenidate (Concerta·Ritalin)·amphetamine (Adderall) — strong effect, dependence·abuse risk, pregnancy·lactation limit
Non-stimulants: Strattera (atomoxetine)·Intuniv·Qelbree — weak effect, 4~6 wk onset

Centanafadine differentiation:

Triple reuptake inhibition: norepinephrine + dopamine + serotonin
Non-stimulant (↓ dependence)
Fast onset (stimulant-level expected)
Depression·anxiety comorbidity effect (serotonin)

Why Especially Meaningful for Women

Non-stimulant preference reasons:

Pregnancy·lactation safety possible
↓ dependence risk
↓ cardiovascular side effects
Depression-comorbid ADHD triple action

Suitable for perimenopausal women:

Dopamine stimulation (stimulant-level)
Serotonin (perimenopausal depression)
Non-stimulant (long-term use)

40 pillar connections:

L66 Auvelity (NMDA depression) → L71 centanafadine (triple ADHD)
L70 SAINT TMS (PPD) → L71 centanafadine (women ADHD)
L70 luvesilocin (psychedelic) → L71 centanafadine (triple reuptake)

Women’s psychiatry blind spot 4th axis.

Common Comorbidities

Depression (50~80%)
Anxiety (40~60%)
Eating disorders (3~4x)
Autoimmune disease ↑
Chronic pain (fibromyalgia)
PMDD·PPD

Korean Clinical Implications

Current Korea: ADHD diagnosis kid-focused, adult ADHD diagnosis gradually increasing, stimulant insurance (Concerta·Medikinet), Strattera partial insurance, women adult ADHD diagnosis very low

Centanafadine expected: FDA approval 2026.7 → Korean MFDS 1~2 years, 2028 expected, price $300~$500/month estimated

Self-Assessment

Adult ADHD ASRS-v1.1: WHO 6-item screening, 4+ = possibility ↑

Women-specific signs: Organization·planning difficulty (housework·kids·work multi), time perception lack (chronic lateness), impulsive decisions (shopping·relationships), chronic fatigue (cognitive burden), childhood depression·anxiety history, perimenopausal worsening

Daily Management

Currently possible (pre-Centanafadine):

Psychiatry evaluation (adult ADHD diagnosis)
CBT-ADHD
Drugs (stimulants·atomoxetine·Strattera)
Time management tools·apps (Todoist·Notion)
Exercise (natural dopamine)
Sleep priority

Perimenopausal women additional: OB-GYN + psychiatry collaboration, HRT dopamine impact monitoring, hormone + ADHD drug adjustment

FAQ

Q. Diagnosed as adult - too late? A. Not late. Women average diagnosis 36. Diagnosis + treatment improves life expectancy·quality. Start anytime.

Q. Stimulant vs Centanafadine? A. Centanafadine US PDUFA 2026.7. Currently stimulants·atomoxetine option. Future Centanafadine added.

Q. Pregnancy ADHD drug? A. Stimulants 1st trimester restricted. Strattera·Centanafadine = psychiatrist decision. OB-GYN + psychiatry collaboration required.

Q. Post-menopause ADHD symptoms stabilize? A. Some stabilization. But hormone·cognition·mood fluctuation continues. ADHD drug + HRT integrated care needed.

Conclusion

Centanafadine FDA Priority Review = women’s ADHD blind spot clinical unit recognition. Triple reuptake non-stimulant·depression-comorbidity·perimenopausal hormone-dopamine axis clinical. L71 = 40 pillars + blind spot dimension (women’s psychiatry 4th axis). Korea 2028 expected. 8.6-year life expectancy gap can be reduced through diagnosis·treatment.

Source: Otsuka / FDA Priority Review